Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 16571-778
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 16571-778). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
The text describes a graph that shows the cumulative percentage of patients based on the change in their ADCS-ADL score from baseline. The graph compares the effects of treatment with Donepezil Hydrochloride 10 mg/day versus a placebo. The horizontal axis represents the change in ADCS-ADL score from baseline, while the vertical axis shows the cumulative percentage of patients at each score level. The graph indicates a higher percentage of patients treated with Donepezil Hydrochloride 10 mg/day have improved scores compared to the placebo group.*
Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
The text above shows a graph representing the cumulative percentage of patients based on the change from baseline in a variable referred to as "SIB". The graph has a range from 0 to 100 on the y-axis and from 0 to 60 on the x-axis.*
Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
Package Label-principal Display Panel (5 mg (100 Tablet Bottle))
Package Label-principal Display Panel (10 mg (30 Tablet Bottle))
This is a medication description for Donepezil Hydrochloride Tablets USP, containing 10 mg of Donepezil hydrochloride USP. The medication is dispensed in tight containers and stored between 20° to 25°C (68° to 77°F); with excursions permitted to 15° to 30°C (59° to 86°F). The usual dosage information can be found in the accompanying prescribing information. The medication is distributed by Rising Pharma Holdings, Inc., Made in India. The NDC code is 16571-779-03.*
Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
Not-Available.
The provided text appears to be a mixture of incomplete and misspelled medical terminology and unclear symbols. It does not form a coherent and understandable description.*
Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
This text shows a graph with the percentages of patients categorized into groups. The categories are not defined. Additionally, there is the name of three treatments: Donepezil Hydrochloride 10mg/day, Donepezil Hydrochloride §mg/day, and Placebo. The graph seems to be related to the effectiveness of these treatments based on "Markedly Improved, Moderately Improved, Minimally Improved, No Change, Worse." Lastly, there is a mention of "CIBIC-plus Rating." *
Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
This is a table displaying the mean change from baseline in SIB (Severe Impairment Battery) scores after 3 months of drug treatment with 10mg/day of Donepezil Hydrochloride compared to Placebo. The table also shows clinical improvement.*
Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
The text describes a graph representing the percentage of patients and their SIB (Severe Impairment Battery) change from baseline. Two drugs were likely being compared, donepezil hydrochloride 10 mg/day and placebo. However, the rest of the graph is not readable, so further information cannot be provided.*
Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
Chemical Structure (Donepezil Str)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
